Key result
Severe liver fibrosis (F3-4) in patients with non-alcoholic fatty liver disease increases the risk of overall mortality by 69% due to cardiovascular causes.
Why the study?
A clear understanding of the impact on cardiovascular risk, the interaction and contribution of various factors, and management algorithms to reduce cardiovascular risk in patients with NAFLD remains lacking.
Design
Review
Authors
Loading...
Severe NAFLD fibrosis may raise CV event risk; hypothesis-generating and should not yet alter practice or risk models.
Severe liver fibrosis in NAFLD significantly increases cardiovascular mortality risk, highlighting the need for targeted cardiovascular risk stratification and pharmacotherapy in these patients.
Нелидова et al. (2022) conducted a review in Non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases. Non-alcoholic fatty liver disease (NAFLD) was evaluated. Severe liver fibrosis (F3-4) in patients with non-alcoholic fatty liver disease increases the risk of overall mortality by 69% due to cardiovascular causes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: